Revolutionizing Biotechnology
News
Worcester, MA, April 16, 2025 – PalenaTherapeutics Inc, developer of novel autoimmune disease therapeutics, has been awarded a U.S. National Science Foundation (NSF) Small Business Innovation Research (SBIR) grant for $305,000 to conduct research and development (R&D) work on its novel immunomodulatoryrandom copolymers, termed Embedded Epitope Random Peptides (EERPs). The grant is focused on using Palena’snovel technology to develop therapeutics for the treatment of juvenile idiopathic arthritis-associated uveitis and pediatric Crohn’sdisease. The Company’s immunomodulatorypeptides represent a new approach for the treatment of autoimmune diseases by reprogramming and not interfering with the function of the immune system to stop disease progression and inflammation which will allow it to function normally to fight infectious diseases. To learn more visit: https://seedfund.nsf.gov/awardees/phase-1/details/?company=palena-therapeutics-inc
Presentations
Poster at the 2024 IRSF Rett Syndrome Scientific Meeting, Westminster, CO, June 18-19, 2024.
Fridkis-Hareli, M. & DiTullio, P. Embedded Epitope Random Peptides as Candidate Therapy for Rett Syndrome.
Presentations
Poster at the 2023 IRSF Rett Syndrome Scientific Meeting, Nashville, TN, June 5-7, 2023.
Fridkis-Hareli, M. & DiTullio, P. Embedded Epitope Random Peptides as Candidate Therapy for Rett Syndrome.
https://www.flickr.com/photos/197165270@N04/sets/72177720309081197/